{
  "docId": "019de073-948a-7043-8b3b-a5ac9bb504f9",
  "docSlug": "d72f38beef66cb68e946399178678a94",
  "documentTitle": "Roivant Sciences | Investor Presentation Deck | 21 slides",
  "authorId": "roivant-sciences",
  "authorName": "Immunovant",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 21,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-948a-7043-8b3b-a5ac9bb504f9/18",
  "deckHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9",
  "deckJsonHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9.json",
  "deckAnchorHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.15,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2b7d45f-a1b5-4497-8723-d6c539d5c8ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.7,
        "x": 0.2,
        "y": 0.25
      },
      "kind": "list",
      "text": "Lead asset batoclimab full speed ahead in pivotal programs for MG, TED and CIDP. Earlier batoclimab launches may provide faster path to positive cash flow. Complementary new asset IMVT-1402 expected to expand opportunity. Patient level data from batoclimab can accelerate IMVT-1402. IMVT-1402 patent protection to 2042.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2da2559c-c964-4c7e-9853-22c84220cbad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "We believe franchise value is maximized by developing both batoclimab and IMVT-1402",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e832094d-56d7-4b5e-a56c-85e44446aa5b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Storytelling: the three headline reasons",
      "slug": "three-reasons",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "68d8e65a-2d9c-41f3-8937-666d94d75ca9",
      "evidence": "list/bullet: Lead asset batoclimab full speed ahead in pivotal programs for MG, TED and CIDP. Earlier batoclimab launches may provide faster path to positive cash flow. Complementary new asset IMVT-1402 expected to expan",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}